Enjoy complimentary customisation on priority with our Enterprise License!
The tourettes syndrome drugs market size is forecast to increase by USD 642.1 million and is estimated to grow at a CAGR of 6.78% between 2023 and 2028. Tourette Syndrome, a neurological disorder characterized by repetitive, involuntary motor and vocal tics, is gaining increased attention due to growing awareness and recognition. The prevalence of this condition is on the rise, with an estimated 1 in 160 children diagnosed worldwide. This surge in cases necessitates the development of cost-effective treatment options to manage the symptoms and improve the quality of life for those affected. Current treatments include medication, behavioral therapy, and education. As research continues to unravel the complexities of Tourette Syndrome, advancements in treatment methods and interventions are expected to provide relief and support for those living with this condition.
For More Highlights About this Report, Request Free Sample
Tourette's Syndrome, a neurodevelopmental disorder characterized by repetitive motor and vocal tics, affects individuals during childhood, adolescence, and adulthood. The market for drugs used to treat Tourette's Syndrome is growing due to the increasing number of diagnosed cases and the need for effective treatment options. Clinical evaluation by healthcare professionals, including neurologists and psychiatrists, plays a crucial role in diagnosis. Behavioral therapies and personalized medicine are among the current treatment methods. Genetic research, animal models, and clinical trials are ongoing to develop new drugs and biomarkers for early intervention. The prevalence of Tourette's Syndrome is estimated to be around 1-2 per 1,000 individuals, with a higher number of pediatric cases. Diagnostic tools and advocacy groups play a significant role in increasing awareness and ensuring early intervention, improving the quality of life for those affected. Other conditions, such as ADHD and OCD, often co-occur with Tourette's Syndrome, adding complexity to diagnosis and treatment. The market is expected to grow due to the unmet medical needs and the potential for new treatment options. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing awareness about Tourette syndrome is notably driving market growth. Tourette's syndrome is a neurodevelopmental disorder characterized by the presence of persistent motor tics and vocal tics, which typically begin in childhood and continue into adolescence and adulthood. The diagnosis of Tourette's syndrome requires clinical evaluation by a healthcare professional, such as a neurologist or psychiatrist.
Moreover, treatment options for Tourette's syndrome include behavioral therapies, such as Comprehensive Behavioral Intervention for Tics (CBIT), and medications. Antipsychotic drugs, adrenergic agonists, and some antidepressants are commonly used medications for managing tics. Comorbid conditions, such as ADHD and OCD, are often present and require additional treatment. Thus, such factors are driving the growth of the market during the forecast period.
Increasing R and D investments for Tourette syndrome is the key trend in the market. Tourettes syndrome, a neurodevelopmental disorder characterized by repetitive motor tics and vocal tics, affects individuals during childhood, adolescence, and adulthood. Diagnosis is based on clinical evaluation by healthcare professionals, including neurologists and psychiatrists. Behavioral therapies, such as Comprehensive Behavioral Intervention for Tics (CBIT), are often the first line of treatment.
However, for severe cases, medications may be prescribed. Antipsychotic drugs, adrenergic agonists, and antidepressants are commonly used medications for Tourettes syndrome. Antipsychotic medications, such as haloperidol and risperidone, target neurotransmitter pathways, specifically dopamine and serotonin. Side effects, including weight gain and extrapyramidal symptoms, limit their long-term use. Thus, such trends will shape the growth of the market during the forecast period.
The social stigma associated with Tourettes syndrome and lack of awareness among people is the major challenge that affects the growth of the market. Tourette's syndrome is a neurodevelopmental disorder characterized by the presence of persistent motor tics and vocal tics, which can affect individuals during childhood, adolescence, and adulthood.
Moreover, the clinical evaluation and diagnosis of Tourette's syndrome involve consultation with healthcare professionals, such as neurologists and psychiatrists, to assess the severity and impact of tics on daily life. Treatment options for Tourette's syndrome include behavioral therapies, such as Comprehensive Behavioral Intervention for Tics (CBIT), and medications. Antipsychotic drugs, adrenergic agonists, and antidepressants are commonly used medications for managing tics. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc: The company offers AZD5213 tourette syndrome drug which is used for the treatment of several neurological disorders
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The antipsychotics segment is estimated to witness significant growth during the forecast period. Tourettes syndrome, a neurodevelopmental disorder characterized by repetitive motor tics and vocal tics, affects individuals during childhood, adolescence, and adulthood. The diagnosis of Tourettes syndrome involves clinical evaluation by healthcare professionals, including neurologists and psychiatrists.
Get a glance at the market share of various regions Download the PDF Sample
The antipsychotics segment was the largest segment and valued at USD 722.10 million in 2018. Treatment options include behavioral therapies, such as Comprehensive Behavioral Intervention for Tics (CBIT), and medications. Antipsychotic drugs, which held the largest share in the global market in 2023, are effective in treating tics. Developed primarily for schizophrenia, these drugs work by blocking dopamine, specifically the D2 receptor, in the brain. Fluphenazine, Haloperidol (Haldol), pimozide (Orap), and risperidone (Risperdal) are commonly used antipsychotic drugs for Tourettes syndrome. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 50% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Tourette Syndrome (TS), a neurological disorder characterized by repetitive, involuntary motor and vocal tics, affects approximately 200,000 Americans, with pediatric cases accounting for the majority. Early intervention is crucial to improve the quality of life for individuals with TS, necessitating the development of advanced diagnostic tools. Advocacy groups and foundations, such as the Tourette Association of America and the Tourette Syndrome Foundation, play a vital role in raising awareness and funding initiatives for research and development in the pharmaceutical industry. Hence, such factors are driving the market in North America during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Tourette's syndrome is a neurodevelopmental disorder characterized by repetitive, involuntary tics involving muscles and vocalizations. Tics can manifest as motor tics, such as eye blinking or facial grimacing, or vocal tics, such as repetitive sounds or words. Tourette's syndrome can affect individuals during childhood, adolescence, and adulthood. Diagnosis is typically made through clinical evaluation by healthcare professionals, including neurologists and psychiatrists. Various treatment options are available for Tourette's syndrome, including behavioral therapies like Comprehensive Behavioral Intervention for Tics (CBIT) and medications. Antipsychotic drugs, such as haloperidol and risperidone, are commonly used to manage tics, but they come with side effects. Adrenergic agonists, like clonidine and guanfacine, and antidepressants are also used to treat Tourette's syndrome. Research into the neurotransmitter pathways involved in Tourette's syndrome, particularly those related to dopamine and serotonin, is ongoing. Targeted drug therapies, such as antipsychotic medications and immunomodulation therapies, are being explored. Comorbid conditions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive-Compulsive Disorder (OCD), can complicate treatment. Clinical trials are underway to develop biomarkers for Tourette's syndrome and explore new treatments, including Deep Brain Stimulation (DBS) and personalized medicine based on genetic research and animal models. Immunomodulation therapies, which target inflammation, are also being investigated. Nonantipsychotic medications, such as tetrabenazine, are being studied for their potential in treating Tourette's syndrome.
Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.78% |
Market growth 2024-2028 |
USD 642.1 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 50% |
Key countries |
US, Germany, UK, China, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, Bausch Health Companies Inc., Catalyst Pharmaceuticals Inc, Eli Lilly and Co., Emalex Biosciences Inc., H Lundbeck AS, Johnson and Johnson Services Inc., Medtronic Plc, Neurocrine Biosciences Inc., Otsuka Holdings Co. Ltd., Paragon Biosciences LLC, Questex LLC, Reviva Pharmaceuticals Holdings Inc, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, market report, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.